Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway
PLOS One · 23.06.2026 · 21 (6) · e0352120
DOI: 10.1371/journal.pone.0352120 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 23.06.2026. Verfasst von Haeun Hwang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Fundamental Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, tau Proteins, Autophagy, Signal Transduction. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
Tauopathies are neurodegenerative diseases characterized by the presence of hyperphosphorylated tau (p-tau) and neurofibrillary tangles. Autophagy is a critical self-degradation mechanism that preserves cellular homeostasis and function, including the clearance of misfolded proteins. Autophagy is impaired in tauopathies, resulting in excessive accumulation of p-tau. Omipalisib, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, was explored in a phase I clinical trial involving solid tumors and lymphoma. In this study, we aimed to investigate the effects of omipalisib on tauopathy both in vitro and in vivo . Omipalisib increased the levels of protein LC3B and decreased that of p62 in human tau (P301L)-expressing SH-SY5Y stable (SH-Tau) cells by inhibiting mTOR activation in a time-dependent manner. In our study, we hypothesized that omipalisib, a PI3K/mTOR inhibitor, could remove accumulated tau and inhibit memory decline by activating autophagy. Additionally, omipalisib reduced tau phosphorylation in SH-Tau cells without inducing cytotoxicity. Upon administration of 6-month-old PS19 mice with omipalisib (1 mg/kg) for 2 months, the levels of both RIPA-soluble and RIPA-insoluble p-tau were decreased, and spatial memory dysfunction was alleviated in omipalisib-treated PS19 mice. Overall, these results show that omipalisib decreases the expression of p-tau by modulation mTOR-autophagy pathway, resulting in the amelioration of spatial memory deficits. This study highlighted the potential of omipalisib as a candidate treatment for tauopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Fundamental Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
- Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
- Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America.
- Department of Neurobiology and Behavior, University of California, Irvine, California, United States of America.
- College of Pharmacy and Institute of Integrated Pharmaceutical Sciences, Kyung Hee University, Seoul, Republic of Korea.
ORCID-Profile: Jong Kil Lee
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Hwang, H., Kim, N., Jeon, S., Lee, Y., Son, J., Jeon, S. H., Lee, Y., Gee, M. S., Inn, K. S., & Lee, J. K. (2026). Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway. PLOS One, 21(6), e0352120. https://doi.org/10.1371/journal.pone.0352120
Vancouver
Hwang H, Kim N, Jeon S, Lee Y, Son J, Jeon SH, et al. Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway. PLOS One. 2026;21(6):e0352120. doi:10.1371/journal.pone.0352120
BibTeX
@article{Hwang2026,
author = {Hwang, Haeun and Kim, Namkwon and Jeon, Subyn and Lee, Yoojin and Son, Jeongmin and Jeon, Seung Ho and Lee, Yeongae and Gee, Min Sung and Inn, Kyung-Soo and Lee, Jong Kil},
title = {Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0352120},
doi = {10.1371/journal.pone.0352120}
}
EUVIMED